Status:
NOT_YET_RECRUITING
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
Lead Sponsor:
University of California, San Francisco
Conditions:
Solid Tumor
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be...
Detailed Description
Primary Objective: 1. To generate a repository of participant-derived tumor models\* and specimens\*\* - annotated with demographic, clinical, and pathologic data - from adults with solid tumor malig...
Eligibility Criteria
Inclusion
- For participants undergoing collection of tissue, ascites, and/or pleural effusions:
- Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
- Individuals 18 years of age or older on the day of signing informed consent.
- Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer.
- Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):
- Surgical resection
- Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted)
- Paracentesis
- Thoracentesis
- For participants undergoing blood banking:
- Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
- Individuals 18 years of age or older on the day of signing informed consent.
- Individuals with a family history or personal history of cancer.
- Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.
Exclusion
- 1\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.
Key Trial Info
Start Date :
January 31 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2035
Estimated Enrollment :
50000 Patients enrolled
Trial Details
Trial ID
NCT06895681
Start Date
January 31 2026
End Date
December 31 2035
Last Update
November 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143